Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

GKL-006Allo Injection in Patients With Advanced Solid Tumors

14 luglio 2026 aggiornato da: Beijing Gene Key Life Technology Co., Ltd

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GKL-006Allo Injection in Patients With Solid Tumors

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of GKL-006Allo Injection in participants with advanced solid tumors.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This Phase 1 study will evaluate GKL-006Allo Injection in participants with advanced or metastatic solid tumors who have failed or are intolerant to standard therapy.

The study includes single-dose and multiple-dose treatment, with a potential dose-expansion stage to further evaluate selected dose level according to protocol-specified criteria. The single-dose and multiple-dose stages are designed to characterize safety, tolerability, and biological activity across protocol-specified dose levels.

Participants will receive GKL-006Allo Injection according to the study protocol and will undergo scheduled safety monitoring, tumor assessments, pharmacokinetic and pharmacodynamic sampling, and immunogenicity testing during treatment and follow-up.

Tipo di studio

Interventistico

Iscrizione (Stimato)

27

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Cancer Hospital Chinese Academy of Medical Sciences
  • Numero di telefono: +86-316-5916013
  • Email: lining@cisams.ac.cn

Luoghi di studio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100021
        • Cancer Hospital Chinese Academy of Medical Sciences
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Able to understand and voluntarily sign the informed consent form.
  • Aged 18 to 75 years.
  • Histologically, cytologically or clinical confirmed unresectable locally advanced or metastatic solid tumor that has failed standard therapy.
  • At least one measurable tumor lesion during screening according to RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and life expectancy of at least 3 months.
  • Adequate hematologic and organ function.
  • Participants of childbearing potential must agree to use at least one medically accepted contraceptive method during study treatment and for 6 months after the end of study treatment.
  • Able to communicate with the investigator, comply with study visits, and understand and follow study requirements.

Exclusion Criteria:

  • Recently received radical radiotherapy or other anti-tumor therapy.
  • Known hypersensitivity to any component of the study treatment.
  • Prior history or concurrent malignancy that has not been cured.
  • Active infection, known or suspected autoimmune disease.
  • Last anti-tumor treatment toxicity not yet recovered to suitable status.
  • Other organ dysfunction or situations deemed inappropriate by the investigator.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: GKL-006Allo Injection
Natural killer T cells (NKT) are a type of special lymphocyte discovered in recent years that mediate both innate and adaptive immunity, and are considered the fourth type of lymphocyte. GKL-006Allo is an allogeneic iNKT cell.
GKL-006Allo Injection is an allogeneic invariant natural killer T (iNKT) cell therapy. It will be administered according to the dose level, dosing schedule, and treatment stage specified in the protocol.
Altri nomi:
  • Allogeneic iNKT Cell Therapy
  • Allogeneic invariant natural killer T cell therapy

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Participants With Dose-Limiting Toxicities (DLTs)
Lasso di tempo: From the first dose through the end of the DLT observation period, assessed up to 28 days.
Dose-limiting toxicities will be assessed according to protocol-defined DLT criteria.
From the first dose through the end of the DLT observation period, assessed up to 28 days.
Incidence and Severity of Adverse Events
Lasso di tempo: From the first dose of study treatment until 28 days after the pointed dose of study treatment. The safety monitor will be continued until the end of the study, up to 18 months.
Safety will be assessed by the incidence and severity of adverse events, serious adverse events, laboratory abnormalities, electrocardiogram abnormalities, physical examination findings, and vital sign abnormalities.
From the first dose of study treatment until 28 days after the pointed dose of study treatment. The safety monitor will be continued until the end of the study, up to 18 months.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-Free Survival (PFS)
Lasso di tempo: From the first dose of study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 18 months.
Progression-free survival is defined as the time from the first dose of study treatment to the first documented disease progression or death from any cause, whichever occurs first, according to RECIST v1.1.
From the first dose of study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 18 months.
Overall Survival (OS)
Lasso di tempo: From the first dose of study treatment until death from any cause, assessed up to 18 months.
Overall survival is defined as the time from the first dose of study treatment to death from any cause.
From the first dose of study treatment until death from any cause, assessed up to 18 months.
Change From Baseline in EORTC QLQ-C30 Scale Scores
Lasso di tempo: Baseline and scheduled post-baseline assessments, up to 18 months.
Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores for each scale range from 0 to 100. Higher scores on the functional scales and global health status/quality-of-life scale indicate better functioning or quality of life.
Baseline and scheduled post-baseline assessments, up to 18 months.
Immunogenicity
Lasso di tempo: From baseline through protocol-specified immunogenicity sampling time points, assessed up to 180 days.
GKL-006 Alloantibodies (ADA) and their titers, anti-GKL-006 Allo neutralizing antibodies (Nab) and their titers, anti-HLA antibodies, etc. will be tested.
From baseline through protocol-specified immunogenicity sampling time points, assessed up to 180 days.
Disease Control Rate (DCR)
Lasso di tempo: From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Disease control rate is defined as the proportion of participants with a best overall response of complete response, partial response, or stable disease according to RECIST v1.1.
From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Objective Response Rate (ORR)
Lasso di tempo: From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Objective response rate is defined as the proportion of participants with a best overall response of complete response or partial response according to RECIST v1.1.
From the first dose of study treatment through scheduled tumor assessments, assessed up to 18 months.
Pharmacokinetic characterization of maximum observed plasma concentration (Cmax)
Lasso di tempo: From 60 minutes before the first dose through 150 days.
Maximum observed plasma concentration of GKL-006 following intravenous administration according to protocol.
From 60 minutes before the first dose through 150 days.
Pharmacokinetic characterization of time to maximum observed plasma concentration (Tmax)
Lasso di tempo: From 60 minutes before the first dose through 150 days.
Time to reach the maximum observed plasma concentration of GKL-006 following intravenous administration.
From 60 minutes before the first dose through 150 days.
Pharmacokinetic characterization of area under the plasma concentration-time curve (AUC)
Lasso di tempo: From 60 minutes before the first dose through 150 days.
Area under the plasma concentration-time curve of GKL-006 following intravenous administration.
From 60 minutes before the first dose through 150 days.
Pharmacokinetic characterization of terminal elimination half-life (t½)
Lasso di tempo: From 60 minutes before the first dose through 150 days.
Terminal elimination half-life of GKL-006 calculated from plasma concentration-time data following intravenous administration.
From 60 minutes before the first dose through 150 days.
Pharmacodynamic Biomarkers of NK cells
Lasso di tempo: From 60 minutes before the first dose through 150 days.
Immune cell subsets
From 60 minutes before the first dose through 150 days.
Pharmacodynamic Biomarkers of Peripheral blood TNF-α
Lasso di tempo: From 60 minutes before the first dose through 150 days.
Immune-related cytokines
From 60 minutes before the first dose through 150 days.
Pharmacodynamic Biomarkers of Peripheral blood IFN-γ
Lasso di tempo: From 60 minutes before the first dose through 150 days.
Immune-related cytokines
From 60 minutes before the first dose through 150 days.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Ning Li, MD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

30 agosto 2026

Completamento primario (Stimato)

30 settembre 2028

Completamento dello studio (Stimato)

31 gennaio 2029

Date di iscrizione allo studio

Primo inviato

9 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

14 luglio 2026

Primo Inserito (Effettivo)

15 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

15 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 luglio 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • GKL006ALLOST01

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi